Lactiplantibacillus plantarum WJL ameliorates chronic kidney disease by inhibiting fibroblast growth factor 21 adaptive stress response via low protein diet.
Gut MicrobesJul 12, 2026 (epub)
Berengère Benoit, Pierre Letourneau, Vincent Verdier et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated the effects of Lactiplantibacillus plantarum WJL supplementation in nondiabetic chronic kidney disease (CKD) patients on a low-protein diet (LPD). The study found that Lp WJL supplementation suppressed fibroblast growth factor 21 induction by 26% and preserved body weight, while still improving kidney and metabolic parameters associated with LPD.
Key findings
- LPD improved glucose tolerance and reduced circulating gut-derived uremic toxins in both mice and humans.
- Lp WJL supplementation suppressed FGF21 induction by 26% in CKD patients on LPD.
- Body mass index decreased by approximately 0.5 kg/m² in humans on LPD.
- In mice, Lp WJL led to a 247% increase in weight gain while on LPD.
Why it matters
Understanding the metabolic effects of low-protein diets and the role of probiotics like Lp WJL can help clinicians optimize dietary interventions in CKD management, potentially improving patient outcomes and minimizing adverse effects.